1 minute read
Feb. 9, 2022

MRTX1133: a Non-Covalent Inhibitor of KRASG12D

Mirati KRASG12D Inhibitor

reversible KRASG12D inhibitor preclinical efficacy in cancer model from SBDD around KRASG12C inhibitor MRTX1133 Mirati Therapeutics, San Diego, CA

drughunter.com
Drug Hunter Team
Reviewer:  

MRTX1133 was nominated as December 2021’s cover molecule by reviewers Joachim Rudolph and Julien Lefranc . MRTX1133 is a non-covalent inhibitor of KRASG12D that demonstrated tumor regression in a mouse xenograft model when dosed IP (maximum efficacy at 10-30 mg/kg, activity as low as 3 mg/kg). Joachim said, “The discovery of MRTX1133 deserves [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in